Intervention Review

You have free access to this content

Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease

  1. Esther J van Zuuren1,*,
  2. Zbys Fedorowicz2

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 12 JUN 2013

Assessed as up-to-date: 5 JUN 2013

DOI: 10.1002/14651858.CD010155.pub2


How to Cite

van Zuuren EJ, Fedorowicz Z. Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD010155. DOI: 10.1002/14651858.CD010155.pub2.

Author Information

  1. 1

    Leiden University Medical Center, Department of Dermatology, Leiden, Netherlands

  2. 2

    The Cochrane Collaboration, UKCC (Bahrain Branch), Awali, Bahrain

*Esther J van Zuuren, Department of Dermatology, Leiden University Medical Center, PO Box 9600, B1-Q, Leiden, 2300 RC, Netherlands. E.J.van_Zuuren@lumc.nl.

Publication History

  1. Publication Status: New
  2. Published Online: 12 JUN 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to ongoing studies
  3. Additional references
Qari 2007 {published data only}
  • Qari MH, Aljaouni SK, Alardawi MS, Fatani H, Alsayes FM, Zografos P, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis 2007;98(2):392-6. [PUBMED: PMID: 17721622]
  • Qari MH, Mousa S, Alsaigh MA, Zografos P, Aljaouni SK, Fatani H, et al. Tinzaparin in the management of painful vaso-occlusive crisis of sickle cell anaemia. Blood 2005;106(11):Abstract no: 2340.

References to ongoing studies

  1. References to studies included in this review
  2. References to ongoing studies
  3. Additional references
NCT01419977 {unpublished data only}
  • NCT01419977. Treatment of sickle cell patients hospitalized in pain crisis with prophylactic dose low-molecular-weight heparin (LMWH) versus placebo. www.clinicaltrials.gov/show/NCT01419977 (accessed 01 March 2013).

Additional references

  1. References to studies included in this review
  2. References to ongoing studies
  3. Additional references
Al Hajeri 2008
Ataga 2012
  • Ataga KI, Brittain JE, Desai P, May R, Jones S, Delaney J, et al. Association of coagulation activation with clinical complications in sickle cell disease. Plos One 2012;7(1):e29786. [PUBMED: PMID: 22253781]
Austin 2007
  • Austin H, Key NS, Benson JM, Lally C, Dowling NF, Whitsett C, et al. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood 2007;110(3):908-12. [PUBMED: PMID: 17409269]
Austin 2009
  • Austin H, Lally C, Benson JM, Whitsett C, Hooper WC, Key NS. Hormonal contraception, sickle cell trait, and risk for venous thromboembolism among African American women. American Journal of Obstetrics and Gynecology 2009;200(6):620.e1-3. [PUBMED: PMID: 19306959]
Ballas 2010
  • Ballas SK, Lieff S, Benjamin LJ, Dampier CD, Heeney MM, Hoppe C, et al. Definitions of the phenotypic manifestations of sickle cell disease. American Journal of Hematology 2010;85(1):6-13. [PUBMED: PMID:19902523]
Ballas 2012
  • Ballas SK, Kesen MG, Goldberg MF, Lutty GA, Dampier C, Osunkwo I, et al. Beyond the definitions of the phenotypic complications of sickle cell disease: An update on management. The Scientific World Journal 2012;2012:949535. [DOI: 10.1100/2012/949535]
Ballas 2013
  • Ballas SK. Sickle cell anemia. http://pier.acponline.org/physicians/diseases/d905/d905.html (accessed 28 February 2013):1-93.
Brown 2006
Bunn 2010
  • Bunn HF, Nathan DG, Dover GJ, Hebbel RP, Platt OS, Rosse WF, et al. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood 2010;116(5):687-92. [PUBMED: PMID:20395414]
Carr 2007
  • Carr JA, Cho JS. Low molecular weight heparin suppresses tumor necrosis factor expression from deep vein thrombosis. Annals of Vascular Surgery 2007;21(1):50-5. [PUBMED: PMID: 17349336]
Davies 2012
  • Davies EG, Hirst C, Lottenberg R, Dower N. Pneumococcal vaccines for sickle cell disease. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD003885.pub2]
De Franceschi 2009
  • De Franceschi L. Pathophisiology of sickle cell disease and new drugs for the treatment. Mediterranean Journal of Hematology and Infectious Diseases 2009;1(1):e2009024. [PUBMED: PMID:21415994]
De Franceschi 2011
de Montalembert 2008
Gladwin 2012
  • Gladwin MT, Sachdev V. Cardiovascular abnormalities in sickle cell disease. Journal of the American College of Cardiology 2012;59(13):1123-33. [PUBMED: PMID:22440212]
Goldsmith 2012
Higgins 2003
Higgins 2011a
  • Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Higgins 2011b
  • Sterne JAC, Egger M, Moher D, on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Higgins 2011c
  • Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org .
Higgins 2011d
  • Higgins JPT, Deeks JJ, Altman DG on behalf of the CSMG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hirani 2011
  • Hirani A, Weibel S, Kane GC. Acute chest syndrome and other pulmonary manifestations of sickle cell disease. Journal of Clinical Outcome Management 2011;18(5):211-21.
Hirsh 1992
Hirsh 2001
  • Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119 Suppl 1:64S-94S. [PUBMED: PMID: 11157643]
Hoy 2010
  • Hoy SM, Scott LJ, Plosker GL. Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis. Drugs 2010;70(10):1319-47. [PUBMED: PMID: 20568836]
Inati 2009
  • Inati A. Recent advances in improving the management of sickle cell disease. Blood Reviews 2009;23 Suppl 1:S9-13. [PUBMED: PMID: 20116638]
Inati 2009b
  • Inati A, Chabtini L, Mounayar M, Taher A. Current understanding in the management of sickle cell disease. Hemoglobin 2009;33 Suppl 1:S107-15. [PUBMED: PMID: 20001613]
Jaywant 2003
  • Jaywant S, Pai A. A comparative study of pain measurement scales in acute burn patients. Indian Journal of Occupational Therapy 2003;35(3):13-7.
Key 2010
  • Key NS, Derebail VK. Sickle-cell trait: novel clinical significance. Hematology/ the Education Program of the American Society of Hematology 2010;2010:418-22. [PUBMED: PMID: 21239829]
Mousa 2003
  • Mousa SA, Bozarth J, Barrett JS. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. Journal of Clinical Pharmacology 2003;43(7):727-34. [PUBMED: PMID: 12856386]
Mousa 2010
  • Mousa SA, Al Momen A, Al Sayegh F, Al Jaouni S, Nasrullah Z, Al Saeed H, et al. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clinical and Applied Thrombosis/Haemostasis 2010;16(4):365-76. [PUBMED: PMID: 20530056]
Rees 2010
RevMan 2011
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Schulz 1995
  • Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
Steinberg 1999
  • Steinberg MH. Management of sickle cell disease. New England Journal of Medicine 1999;340(13):1021-30. [PUBMED: PMID: 10099145]
Steinberg 2011
  • Steinberg MH. In the Clinic. Sickle cell disease. Annals of Internal Medicine 2011;155(5):ITC31-15. [PUBMED: 21893620]
WHO 2006
  • World Health Organization. Sickle-cell anaemia. Report A59/9. Provisional agenda item 11.4. 59th World Health Assembly. https://apps.who.int/gb/ebwha/pdf_files/WHA59/A59_9-en.pdf (accessed 13 March 2012).